SAN DIEGO, Calif. (March 9, 2009)—The so-called "male lumpectomy"—a minimally invasive interventional radiology treatment for prostate cancer—is as effective as surgery in destroying diseased tumors and can be considered a first-line treatment for patients of all risk levels and particularly those who have failed radiation, according to studies released at the Society of Interventional Radiology's 34th Annual Scientific Meeting. Additionally, the use of 3-D transperineal mapping biopsy for determining the extent of prostate cancer—when compared with the commonly used transrectal ultrasound (TRUS) biopsy—heavily impacted how patients' disease was managed in 70 percent of the cases.
"Our data show that focal cryoablation is as good for prostate cancer control as any other treatment—including surgery, radiation and hormone therapy—but it is less invasive and traumatic for patients, preserves sexual and urinary function and has no major complications. Interventional radiologists tailor treatment to each patient's disease. Instead of removing the entire prostate, or freezing the entire prostate or using radiation on the entire prostate, interventional radiologists can find out where the cancer is and just destroy the cancer," said study author Gary M. Onik, M.D., interventional radiologist and director of the Center for Safer Prostate Cancer Therapy in Orlando, Fla. "We've reached a tipping point: treating only the tumor instead of the whole prostate gland is a major and profound departure from the current thinking about prostate cancer," added Onik. With cryoablation, interventional radiologists insert a probe through the skin, using imaging to guide the needle to the tumor; the probe then circulates extremely cold gas to freeze and destroy the cancerous tissue. This minimally invasive treatment targets only the cancer itself, sparing healthy tissue in and around the prostate gland rather than destroying it, as traditional approaches do, noted the professor at the University of Central Florida. "You can go home on the same day of the procedure, and you can repeat the treatment, if needed, in later years," said Onik. Additionally, Onik presented results of a 3-D biopsy method that provides superior information on the extent and grade of prostate cancer as opposed to the current standard TRUS biopsy.
Calling focal cryoablation a "male lumpectomy" reflects the origins of this approach in the breast-sparing surgery that replaced radical mastectomy as the preferred treatment for breast cancer, said Onik. Unlike breast lumpectomy, a surgical lumpectomy for prostate cancer is not technically feasible; so to treat just a portion of the prostate, minimally invasive cryoablation is needed. Cryoablation (or cryo or cryotherapy) spares as much as possible of the prostate gland and its neurovascular bundles, limiting the side effects of bladder control problems (incontinence) and erectile dysfunction (impotence) that result from more radical prostate cancer treatments. It also represents an advantage over "watchful waiting," because all treatment options are preserved. "Any risks are fewer and lesser in intensity than surgery; so if you have the equivalent chance of cancer being cured with far less chance of having any complications, why wouldn't you choose it?" asked Onik.
"There is no question that we can eradicate prostate cancer (when that cancer has not spread to other parts of the body) by freezing it and that there is a better way to 'map' the disease," said Onik. He studied 120 men who had focal cryoablation over the past 12 years, including testing the levels of prostate-specific antigen (PSA) in the blood. Of those patients, 112 (93 percent) had no evidence of cancer—in spite of 72 being labeled medium to high risk for cancer recurrence. "There were no local recurrences in the areas we treated, and with the ability to re-treat the 7 percent of patients who developed a focus of cancer at a different site in the gland; cryoablation was 100 percent effective in local control of the patient's disease," said Onik. He reported that 85 percent of the men retained sexual function. Of those who did not have previous prostate surgery, all remained continent. "Incontinence becomes a big issue with many patients. For some it's a more important side effect than impotence," said Onik.
According to Onik, the 3-D transperineal biopsy complements the focal cryoablation approach because earlier detection of smaller tumors increases the likelihood that a small tumor can be treated using cryoablation. In his study, Onik restaged 180 patients who had previously undergone TRUS mapping biopsies who were considering conservative management for their cancer. The results showed that 70 percent of the men would have their management changed by the new information provided by mapping. Through mapping, more than 50 percent of men who were diagnosed with cancer on one side of the prostate gland with traditional TRUS biopsy had undetected cancer on the other side as well, he said. Management of prostate cancer is in great part determined by the Gleason score, a cancer ranking method indicating tumor grade and stage and the extent and location of a patient's disease. "When we restaged the men, we found that 22 percent of them experienced an increase in their Gleason score—meaning that they had a more aggressive cancer than was originally thought from their original biopsy. The 3-D mapping biopsy provided life-saving information," said Onik. "This biopsy technique allows us to map the location of the tumor with tremendous precision and has the potential to greatly affect the decisions we make about treating prostate cancer," Onik said. "The data are unequivocal. If you're doing 'watchful waiting,' get mapped. If you're having radiation or hormone therapy or thinking about getting a 'nerve-sparing' radical prostatectomy, get mapped. If TRUS doesn't show all the cancer that's present, you're not going to have the proper treatment," said Onik.
With 3-D transperineal mapping, a grid placed over the perineum (the area of skin between the rectum and the scrotum) allows an interventional radiologist to accurately map the location of each biopsy core removed. The cores are taken through the skin rather than through the rectum, allowing many more cores to be removed—about 50 compared to 10-12 in a TRUS biopsy. The mapping grid also allows the location of the tumor to be known much more precisely, allowing an interventional radiologist to cryoablate (freeze) only the tumor and not the whole prostate gland.
Controversy surrounds the treatment of prostate cancer, which usually grows slowly and initially remains confined to the prostate gland, said Onik. Growing evidence of overdetection and overtreatment in many men with low-risk tumors has led to a concept in the medical community of "watchful waiting" or observing a man's disease progression prior to initiating treatment. Many patients, however, feel uncomfortable with this strategy and may proceed to radical or aggressive treatment, said Onik. "When men must choose between 'watchful waiting' and high-morbidity whole-gland treatments (like surgery and radiotherapy), a lumpectomy-type treatment, which has so markedly changed the management of breast cancer for women, is a welcome 'middle ground' addition for those with prostate cancer," said Onik.
"Interventional cryoablation for prostate cancer is not experimental. This is a treatment option that doctors should discuss with their patients early on," emphasized Onik. Most people don't realize that you can surgically remove the whole prostate and, in 20 percent of the cases, the cancer can be left (called a positive margin), said Onik, who works in consultation with urologists. Doctors should discuss cryoablation with patients early on, he advised, noting that recently the American Urological Association issued a best practice statement that indicated that cryotherapy is an option for men who have clinically organ-confined prostate cancer of any grade with negative metastatic evaluation. Since this interventional treatment is not widely known to doctors and patients, individuals will need to pursue it on their own, he added.
More information about prostate cancer, cryoablation and interventional radiology can be found online at www.SIRweb.org.
Abstract 75: "Focal Therapy for Prostate Cancer—120 Patients With Up to 12-Year Follow-up," G. Onik, Center for Safer Prostate Cancer Therapy, Orlando, Fla., SIR 34th Annual Scientific Meeting March 7-12, 2009.
Abstract 198: "3D Prostate Mapping Biopsy Has a Potentially Significant Impact on Prostate Cancer Management," G. Onik, M. Miessau; Center for Safer Prostate Cancer Therapy, Orlando, Fla., SIR 34th Annual Scientific Meeting March 7, 2009. Both abstracts can be found at www.SIRmeeting.org.
About Prostate Cancer
Prostate cancer, the most common non-skin cancer in America, forms in the tissues of the prostate (a gland in the male reproductive system found below the bladder and in front of the rectum). Prostate cancer affects one in six men, usually older men. As men age, the prostate may get bigger and block the urethra or bladder. This may cause difficulty in urination or can interfere with sexual function. It is estimated that there are more than 2 million American men currently living with prostate cancer. Older age, African American race and a family history of the disease can all increase the likelihood of a man being diagnosed with the disease. As men increase in age, their risk of developing prostate cancer increases exponentially. An estimated 230,000 new cases are diagnosed annually in the United States, with nearly 30,000 annual deaths. African American men have higher incidence and at least double the mortality rates compared with men of other racial and ethnic groups. Historically, prostate cancer has been considered an older man's disease; however the incidence is increasing in men in their 40s and 50s.
Prostate cancer usually grows slowly and initially remains confined to the prostate gland. While some types of prostate cancer grow slowly and may need minimal or no treatment, other types are aggressive and can spread quickly. A diagnosis of prostate cancer can be scary not only because it can be life-threatening, but also because invasive treatments can cause side effects such as bladder control problems and erectile dysfunction (impotence). Men are classified as being at low, intermediate or high risk. The criteria used to categorize the risk include the results of the prostate-specific antigen (PSA) blood test (which looks for a protein produced by the prostate gland and can help detect cancer), tumor aggressiveness and the clinical stage of the tumor.
About the Society of Interventional Radiology
Interventional radiologists are physicians who specialize in minimally invasive, targeted treatments. They offer the most in-depth knowledge of the least invasive treatments available coupled with diagnostic and clinical experience across all specialties. They use X-ray, MRI and other imaging to advance a catheter in the body, usually in an artery, to treat at the source of the disease internally. As the inventors of angioplasty and the catheter-delivered stent, which were first used in the legs to treat peripheral arterial disease, interventional radiologists pioneered minimally invasive modern medicine. Today, interventional oncology is a growing specialty area of interventional radiology. Interventional radiologists can deliver treatments for cancer directly to the tumor without significant side effects or damage to nearby normal tissue.
Today many conditions that once required surgery can be treated less invasively by interventional radiologists. Interventional radiology treatments offer less risk, less pain and less recovery time compared to open surgery. Visit www.SIRweb.org.
An estimated 5,300 people are attending the Society of Interventional Radiology's 34th Annual Scientific Meeting in San Diego.
Local interviews and broadcast-quality video footage are available by contacting SIR's communications department at mverrillo@SIRweb.org.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.